Pharmacological mechanism-based drug safety assessment and prediction

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 6, 2011, Pages 793-797

  Abernethy, D R ^a   Woodcock, J ^a   Lesko, L J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOINFORMATICS; DRUG INDUSTRY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; NATIONAL HEALTH ORGANIZATION; PREDICTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RISK BENEFIT ANALYSIS; STUDY DESIGN; SYSTEMS BIOLOGY;

ANIMALS; DRUG INDUSTRY; DRUG TOXICITY; FORECASTING; HUMANS; PHARMACEUTICAL PREPARATIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79956321442     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.55     Document Type: Article

References (42)

1. Guengerich, F.P. & MacDonald, J.S. Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol. 20, 344-369 (2007). (Pubitemid 46548682)
2. Stevens, J.L. Future of toxicology-mechanisms of toxicity and drug safety: where do we go from here? Chem. Res. Toxicol. 19, 1393-1401 (2006). (Pubitemid 44867987)
3. Cook, D. Improving drug safety using computational biology. Drugs 13, 85-89 (2010).
4. Scheiber J. & Jenkins J.L. Chemogenomic analysis of safety profling data. Methods Mol. Biol. 575, 207-223 (2009).
5. Tohkin, M., Ishiguro, A., Kaniwa, N., Saito, Y., Kurose, K. & Hasegawa, R. Prediction of severe adverse drug reactions using pharmacogenetic biomarkers. Drug Metab. Pharmacokinet. 25, 122-133 (2010).
6. Yang, L., Xu, L. & He, L. A CitationRank algorithm inheriting Google technology designed to highlight genes responsible for serious adverse drug reaction. Bioinformatics 25, 2244-2250 (2009).
7. Center for Drug Evaluation and Research. Guidance for Industry. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ ucm079262.pdf.
8. Meyboom, R.H., Egberts, A.C., Edwards, I.R., Hekster, Y.A., De Koning, F.H. & Gribnau, F.W. Principles of signal detection in pharmacovigilance. Drug Saf. 16, 355-365 (1997). (Pubitemid 27326043)
9. Cobert B.L. & Biron P. Pharmacovigilance from A to Z: Adverse Drug Event Surveillance 191-192 (Blackwell Science, Oxford, UK, 2002).
10. Szarfman, A., Machado, S.G. & O'Neill, R.T. Use of screening algorithms and computer systems to efciently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 25, 381-392 (2002). (Pubitemid 34729136)
11. Hauben, M. & Aronson, J.K. Defning 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous defnitions. Drug Saf. 32, 99-110 (2009).
12. Navarro, V.J. & Senior, J.R. Drug-related hepatotoxicity. N. Engl. J. Med. 354, 731-739 (2006). (Pubitemid 43247143)
13. Nolin T.D. & Himmelfarb j. Mechanisms of drug-induced nephrotoxicity. Handb. Exp. Pharmacol. 196 (Part 1), 111-130 (2010).
14. Force, T. Introduction to cardiotoxicity review series. Circ. Res. 106, 19-20 (2010).
15. Dropcho, E.J. Neurotoxicity of cancer chemotherapy. Semin. Neurol. 30, 273-286 (2010).
16. Flanagan, R.J. & Dunk, L. Haematological toxicity of drugs used in psychiatry. Hum. Psychopharmacol. 23 (suppl. 1), 27-41 (2008). (Pubitemid 351166610)
17. O'Connell, T.M. & Watkins, P.B. The application of metabonomics to predict drug-induced liver injury. Clin. Pharmacol. Ther. 88, 394-399 (2010).
18. Fermini, B. & Fossa, A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev. Drug Discov. 2, 439-447 (2003). (Pubitemid 37361725)
19. Frid, A.A. & Matthews, E.J. Prediction of drug-related cardiac adverse efects in humans-B: use of QSAR programs for early detection of drug-induced cardiac toxicities. Regul. Toxicol. Pharmacol. 56, 276-289 (2010).
20. Stang, P.E. et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann. Intern. Med. 153, 600-606 (2010).
21. Dullabh, P., Moiduddin, A. & Babalola, E. Measurement of the utilization of an installed electronic health record. Stud. Health Technol. Inform. 160, 81-85 (2010).
22. Benjamin,Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Statist. Soc. Ser. B 57, 289-300 (1995).
23. Relling, M.V., Altman, R.B., Goetz, M.P. & Evans, W.E. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol. 11, 507-509 (2010).
24. Roberts, P.J., Stinchcombe, T.E., Der, C.J. & Socinski, M.A. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J. Clin. Oncol. 28, 4769-4777 (2010).
25. Dias-Santagata, D. et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol. Med. 2, 146-158 (2010).
26. Swann, J.P. History of the FDA. http://www.fda.gov/AboutFDA/Whatwedo/ History/default.htm.
27. US Food and Drug Administration. FDA Amendments Act (FDAAA) of 2007. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFood DrugandCosmeticActFDCAct/SignifcantAmendmentstotheFDCAct/ FoodandDrugAdministrationAmendmentsActof2007/default.htm.
28. Routledge, P. 150 years of pharmacovigilance. Lancet 351, 1200-1201 (1998). (Pubitemid 28171836)
29. Commission on Anesthetics. Lancet i, 629-638 (1893).
30. McBride W.G. Thalidomide and congenital anomalies. Lancet ii, 1358 (1961).
31. st century: new systematic tools for an old problem. Pharmacotherapy 24, 1099-1104 (2004). (Pubitemid 39128833)
32. Chan-Tack, K.M., Struble, K.A. & Birnkrant, D.B. Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System. AIDS Patient Care STDS 22, 843-850 (2008).
33. Bender, A. et al. Analysis of pharmacology data and the prediction of adverse drug reactions and of-target efects from chemical structure. ChemMedChem. 2, 861-873 (2007).
34. Campillos, M., Kuhn, M., Gavin, A.C., Jensen, L.J. & Bork, P. Drug target identifcation using side-efect similarity. Science 321, 263-266 (2008). (Pubitemid 351989100)
35. Scheiber, J. et al. Mapping adverse drug reactions in chemical space. J. Med. Chem. 52, 3103-3107 (2009).
36. Chiang, A.P. & Butte, A.J. Data-driven methods to discover molecular determinants of serious adverse drug events. Clin. Pharmacol. Ther. 85, 259-268 (2009).
37. Oprea, T.I., Tropsha, A., Faulon, J.L. & Rintoul, M.D. Systems chemical biology. Nat. Chem. Biol. 3, 447-450 (2007). (Pubitemid 47080379)
38. Edwards, S.W. & Preston, R.J. Systems biology and mode of action based risk assessment. Toxicol. Sci. 106, 312-318 (2008).
39. Mudd, P.N. jr, Groenendaal, H., Bush, M.A. & Schmith, V.D. Probabilistic risk analysis: improving early drug development decision making. Clin. Pharmacol. Ther. 88, 871-875 (2010).
40. Lesko, L.J., Zineh, I. & Huang, S.M. What is clinical utility and why should we care? Clin. Pharmacol. Ther. 88, 729-733 (2010).
41. Yang, X., Huang, Y., Crowson, M., Li, J., Maitland, M.L. & Lussier, Y.A. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data. J. Biomed. Inform. 43, 376-384 (2010).
42. Platt, R., Wilson, M., Chan, K.A., Benner, J.S., Marchibroda, J. & McClellan, M. The new Sentinel Network-improving the evidence of medical-product safety. N. Engl. J. Med. 361, 645-647 (2009).